Table 1 Baseline clinical and MRI characteristics of all patients and separately for patients that have and have not achieved DMARD-free sustained remission
| Â | All patients (n = 238) | DMARD-free sustained remission (n = 46) | No remission (n = 192) |
|---|---|---|---|
Clinical characteristics | |||
 Age in years, mean (SD) | 57 (14) | 62 (13) | 55 (14) |
 Female gender, n (%) | 157 (66) | 28 (61) | 129 (67) |
 Symptom duration in weeks | 15 (7–32) | 14 (5–21) | 17 (7–34) |
 Symptom duration > 12 weeks, n (%) | 100 (42) | 20 (44) | 80 (42) |
 HAQ score, mean (SD) | 0.9 (0.6) | 1.1 (0.5) | 1.0 (0.9) |
 68-TJC | 8 (4–14) | 9 (5–17) | 8 (4–13) |
 66-SJC | 5 (2–10) | 8 (3–13) | 5 (2–10) |
 CRP mg/L | 9 (3–21) | 17 (9–27) | 8 (3–20) |
 ESR mm/h, mean (SD) | 30 (24) | 33 (25) | 29 (24) |
 ACPA-positive, n (%) | 120 (50) | 6 (13) | 114 (59) |
 RF-positive, n (%) | 140 (59) | 16 (35) | 124 (65) |
MRI characteristics | |||
 BME score | 3.5 (1.0–8.0) | 4.0 (1.4–7.3) | 3.5 (1.0–8.5) |
 Synovitis score | 5.0 (2.5–9.5) | 7.3 (3.0–10.0) | 4.5 (2.5–9.5) |
 Tenosynovitis score | 4.0 (1.5–7.5) | 4.5 (1.8–9.3) | 4.0 (1.5–7.0) |
 Total MRI inflammation score | 13.5 (6.5–26.0) | 16.5 (6.4–27.6) | 12.5 (6.5–25.5) |